Japan Diabetes Market, Size, Forecast 2023-2028, By Insulin Pump, CGM, Self-Monitoring Blood Device and Company Analysis
Japan Diabetes Market Outlook
Japan's Diabetes Market will reach US $3.39 Billion in 2028, and it will expand at a CAGR of 2.75% from 2023 to 2028, according to Renub Research. Diabetes is a non-communicable disease caused by high blood glucose levels and is currently one of Japan's most important public health problems. Japan has around 11 million people with diabetes, according to IDF 2021. Aging and obesity contribute to the increase in diabetes prevalence. Of this, the rapidly aging population is a significant concern, which makes disease management a challenge. Apart from disease management, the economic impact of diabetes in Japan is substantial.
Ageing Population will Foster the Growth of Japan's Diabetes Market
Japan has the highest proportion of the aging population globally; almost a quarter of the population is 65 plus. The increase in the geriatric population is an enormous burden for the Japanese government because the prevalence of the aging disease is rising rapidly. So the Japanese government has prioritized dealing with an aging population, and it is expected that government will allocate a skyrocketed healthcare budget in 2025 for aging. Therefore rising prevalence and increased public expenditure will boost Japan's diabetes Market. Japan, Diabetes Market was US$ 2.88 Billion in 2022.
Type 2 Diabetes is Increasing Year on Year
Japan has a low incidence of type 1 diabetes because the Japanese are genetically homogeneous. However, Japan has one of the largest elderly populations in the world, which is more susceptible to the onset of type 2 diabetes. In addition, there are many contributing factors to diabetes development in Japanese people, including dietary patterns, physical inactivity, smoking, and many others. Therefore, Japan's diabetes care devices are one of the high-potential markets for development.
SMBG Devices is one of the most Prominent Markets
Japan's Diabetes industry has been divided into SMBG, CGM, and Insulin Pumps. SMBG holds a substantial revenue share owing to the high diabetes incidence rate. In addition, changing lifestyles, unhealthy dietary habits, physical inactivity, and excessive body weight are prominent factors contributing to the disease burden. Thus, the need to monitor blood glucose level for the optimization of treatment regime among these patients drive the japan market revenue. Moreover, a higher prevalence rate across developed countries with awareness regarding SMBG among the type 2 diabetes population will fuel the market revenue.
Japan Government Initiative
Even with such colossal healthcare and drug expenditure on the treatment of diabetes, the number of patients undergoing dialysis due to diabetes continues to increase, and the number of chronic dialysis patients in Japan per capita is by far the largest in an international comparison. To reduce ever-increasing social security expenditure, the Government of Japan is attempting to improve the efficiency of healthcare services. The premise of these efforts is that there exists a high degree of waste in the present system. However, the problem lies in the over-provision of health care and extends to under-provision. In recent years, Japan's disease structure has been changing due to the rapid aging of the population and lifestyle changes.
As a result, there are ever-increasing deaths and disabilities associated with non-communicable diseases (NCDs), such as cancer, cardiovascular diseases, and diabetes. Moreover, these NCDs have accounted for more than 30% of national healthcare expenditures. Therefore, in 2000, the Japanese government launched the National Health Promotion Movement in the 21st Century, known as Health Japan 21.
Key Company
The major players are Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care.
- In June 2022, Sanofi and Health2Sync announced that they would work together on new features such as connected caps for insulin products that can automatically record delivered doses, rather than requiring them to be logged manually, and titration alerts from the app to indicate when a change in insulin dose may be required.
- In March 2022, Quantum Operation Inc., a Tokyo-based healthcare IoT startup, presented the world's first non-invasive glucose monitor capable of continuous measurement. It measures the blood sugar from the wrist without any pricks.
Renub Research report titled “Japan Diabetes Market & Forecast, By Self-Monitoring Blood Glucose (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Insulin Pump (Users, Market & Differentiation Points of Insulin Pump Products, Training Model for Patients & HCP, Reimbursement Policies) Company (Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, Tandem Diabetes Care)” provides a complete analysis of Japan Diabetes Market.
Segments Market based on Devices
1. Continuous Glucose Monitoring (CGM)
2. Self-Monitoring Blood Glucose (SMBG)
3. Insulin Pump
Japan Diabetes Sub-Segment Analysis
1. Self-Monitoring Blood Glucose Device (SMBG)
1. Test Strips Market
2. Lancet Market
3. Meter Market
4. Blood Glucose (SMBG) Users
5. Blood Glucose Devices Reimbursement
2. Continuous Glucose Monitoring (CGM)
1. Glucose Sensor Market
2. CGM Transmitter Market
3. CGM User
4. CGM Reimbursement
3. Insulin Pump Market
1. Insulin Pump Market
2. Insulin Pump Users
3. Reimbursement Policies
All the 7 Companies Studied in the Report have been Studied from 3 Points
• Company Overview
• Recent Developments
• Financial Insight
Company Analysis
1. Medtronic
2. Insulet Corporation
3. Abbott Laboratories
4. DarioHealth Crop
5. Dexcom, Inc
6. Roche Diagnostic
7. Tandem Diabetes Care
Report Details:
| Report Features | Details |
| Base Year | 2022 |
| Historical Period | 2017 - 2022 |
| Forecast Period | 2023 - 2028 |
| Market | US$ Billion |
| Segment Covered | SMBG, CGM, and Insulin Pump |
| Companies Covered | Medtronic, Insulet Corporation, Abbott Laboratories, DarioHealth Crop, Dexcom, Inc, Roche Diagnostic, and Tandem Diabetes Care |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Japan Diabetes Market
6. Japan Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes
7. Share Analysis - Japan Diabetes Market
7.1 By Types
8. Continuous Glucose Monitoring Market (CGM) – Japan Market & Users
8.1 Japan - CGM Market by Components
8.1.1 Glucose Sensor Market
8.1.2 CGM Transmitter Market
8.2 CGM User
8.3 Reimbursement Policies of CGM Devices in Japan
9. Blood Glucose Device (SMBG) –Japan Market & Users
9.1 Market
9.1.1 Type 1 Diabetes Market
9.1.2 Type 2 Diabetes Market
9.2 Test Strips Market
9.2.1 Type 1 Diabetes
9.2.2 Type 2 Diabetes
9.3 Lancet Market
9.3.1 Type 1 Diabetes
9.3.2 Type 2 Diabetes
9.4 Meter Market and Forecast
9.4.1 Type 1 Diabetes
9.4.2 Type 2 Diabetes
9.5 Blood Glucose (SMBG) Users
9.5.1 Type 1 Diabetes
9.5.2 Type 2 Diabetes
9.6 Reimbursement Policies of Blood Glucose Devices in Japan
10. Insulin Pump – Japan Market & Users
10.1 Insulin Pump Market
10.1.1 Type 1 Diabetes Market
10.1.2 Type 2 Diabetes Market
10.2 Insulin Pump User
10.2.1 Type 1 Insulin Pump User
10.2.2 Type 2 Insulin Pump User
10.3 Differentiation Points of Insulin Pump Products in Japan
10.3.1 Animas Vibe
10.3.2 Medtronic 530G with Enlite
10.3.3 InsuletOmniPod
10.3.4 Tandem t: slim
10.3.5 Roche Accu-Chek Combo
10.4 Training Model for Patients & HCP – of Medtronic, Animas, Insulet Corp & Tandem Diabetes Care
10.4.1 Medtronic
10.4.1.1 Training Guidelines for Insulin Pump Therapy to New Patients
10.4.1.2 Training Model for HCP (HealthCare Professional)
10.5 Insulet Corporation
10.5.1 Training Structure for New Patients - Insulet Corporation
10.6 Animas Corporation
10.6.1 Training Modules for New Patients
10.6.2 Training Modules for HCP (Health Care Professional)
10.7 Tandem Diabetes Care
10.8 Reimbursement Policies Insulin Pump
11. Insulin Pump – Company Analysis
11.1 Medtronic
11.1.1 Overview
11.1.2 Recent Development
11.1.3 Revenue
11.2 Insulet Corporation
11.2.1 Overview
11.2.2 Recent Development
11.2.3 Revenue
12. SMBG – Company Analysis
12.1 Abbott Laboratories
12.1.1 Business Overview
12.1.2 Recent Development
12.1.3 Revenue
12.2 DarioHealth Corp
12.2.1 Business Overview
12.2.2 Recent Development
12.2.3 Revenue
13. CGM – Company Analysis
13.1 DexcomInc
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Revenue
13.2 Roche
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Revenue
13.3 Tandem Diabetes Care
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Revenue
List of Figures:
Figure-01: Japan – Diabetes Market (Billion US$), 2017 – 2022
Figure-02: Japan – Forecast for Diabetes Market (Billion US$), 2023 – 2028
Figure-03: Japan – Type 1 Diabetes Population (Thousand), 2017 – 2022
Figure-04: Japan – Forecast for Type 1 Diabetes Population (Thousand), 2023 – 2028
Figure-05: Japan – Type 2 Diabetes Population (Thousand), 2017 – 2022
Figure-06: Japan – Forecast for Type 2 Diabetes Population (Thousand), 2023 – 2028
Figure-07: Japan – Glucose Sensor Market (Million US$), 2017 – 2023
Figure-08: Japan – Forecast for Glucose Sensor Market (Million US$), 2023 – 2028
Figure-09: Japan – CGM Transmitter Market (Million US$), 2017 – 2023
Figure-10: Japan – Forecast for CGM Transmitter Market (Million US$), 2023 – 2028
Figure-11: Japan – CGM User (Thousand), 2017 – 2023
Figure-12: Japan – Forecast for CGM User (Thousand),2023 – 2028
Figure-13: Japan – Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-14: Japan – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-15: Japan – Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-16: Japan – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-17: Japan – Test Strips Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-18: Japan – Forecast for Test Strips Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-19: Japan – Test Strips Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-20: Japan – Forecast for Test Strips Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-21: Japan – Lancet Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-22: Japan – Forecast for Lancet Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-23: Japan – Lancet Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-24: Japan – Forecast for Lancet Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-25: Japan – Meter Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-26: Japan – Forecast for Meter Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-27: Japan – Meter Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-28: Japan – Forecast for Meter Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-29: Japan – Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2017 – 2022
Figure-30: Japan – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 1 Users (Thousand), 2023 – 2028
Figure-31: Japan – Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2017 – 2022
Figure-32: Japan – Forecast for Self-Monitoring of Blood Glucose (SMBG) Type 2 Users (Thousand), 2023 – 2028
Figure-33: Japan – Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2017 – 2023
Figure-34: Japan – Forecast for Insulin Pump Market for Type 1 Diabetes Market (Million US$), 2023 – 2028
Figure-35: Japan – Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2017 – 2023
Figure-36: Japan – Forecast for Insulin Pump Market for Type 2 Diabetes Market (Million US$), 2023 – 2028
Figure-37: Japan – Insulin Pump Type 1 Users (Thousand), 2017 – 2022
Figure-38: Japan – Forecast for Insulin Pump Type 1 Users (Thousand), 2023 – 2028
Figure-39: Japan – Insulin Pump Type 2 Users (Thousand), 2017 – 2022
Figure-40: Japan – Forecast for Insulin Pump Type 2 Users (Thousand), 2023 – 2028
Figure-41: Medtronic – Global Revenue (Billion US$), 2017 – 2022
Figure-42: Medtronic – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-43: Insulet Corporation – Global Revenue (Million US$), 2017 – 2022
Figure-44: Insulet Corporation – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-45: Abbott Laboratories – Global Revenue (Billion US$), 2017 – 2022
Figure-46: Abbott Laboratories – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-47: DarioHealth Corp – Global Revenue (Million US$), 2017 – 2022
Figure-48: DarioHealth Corp – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-49: Dexcom Inc – Global Revenue (Million US$), 2017 – 2022
Figure-50: Dexcom Inc – Forecast for Global Revenue (Million US$), 2023 – 2028
Figure-51: Roche – Global Revenue (Billion US$), 2017 – 2022
Figure-52: Roche – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-53: Tandem Diabetes Care – Global Revenue (Million US$), 2017 – 2022
Figure-54: Tandem Diabetes Care – Forecast for Global Revenue (Million US$), 2023 – 2028
List of Tables:
Table-01: Japan – Diabetes Market Share by Type (Percent), 2017 – 2022
Table-02: Japan – Forecast for Diabetes Market Share by Type (Percent), 2023 – 2028
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com